# A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

> **NCT00618124** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Solid Tumors
- Breast Cancer
- Neoplasms

## Interventions

- **DRUG:** SU011248; Capecitabine

## Key facts

- **NCT ID:** NCT00618124
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2010-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00618124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00618124, "A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00618124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*